These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 27513668)
1. Ingenol Mebutate for Recalcitrant Chronic Actinic Cheilitis. Tzika E; Masouyé I; Mühlstädt M; Laffitte E Dermatology; 2016; 232 Suppl 1():1-3. PubMed ID: 27513668 [TBL] [Abstract][Full Text] [Related]
2. Ingenol mebutate gel treatment for actinic cheilitis: report of four cases. Barrado Solís N; Molés Poveda P; Lloret Ruiz C; Pont Sanjuan V; Velasco Pastor M; Quecedo Estébanez E; Miquel Miquel J Dermatol Ther; 2015; 28(2):79-82. PubMed ID: 25545762 [TBL] [Abstract][Full Text] [Related]
3. Management of actinic cheilitis using ingenol mebutate gel: A report of seven cases. Flórez Á; Batalla A; de la Torre C J Dermatolog Treat; 2017 Mar; 28(2):149-151. PubMed ID: 27241280 [TBL] [Abstract][Full Text] [Related]
4. Dermoscopy and reflectance confocal microscopy for monitoring the treatment of actinic cheilitis with ingenol mebutate gel: Report of three cases. Benati E; Pampena R; Bombonato C; Borsari S; Lombardi M; Longo C Dermatol Ther; 2018 Jul; 31(4):e12613. PubMed ID: 29687567 [TBL] [Abstract][Full Text] [Related]
5. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer. Erlendsson AM Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209 [TBL] [Abstract][Full Text] [Related]
11. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. Berman B; Nestor MS; Newburger J; Park H; Swenson N J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702 [TBL] [Abstract][Full Text] [Related]
12. Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization. Gaide O; Clayton H; Girardin M; Kuonen F Dermatology; 2016; 232 Suppl 1():7-8. PubMed ID: 27513862 [TBL] [Abstract][Full Text] [Related]
13. Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization. Kostovic K; Gulin SJ; Mokos ZB; Ceovic R Anticancer Agents Med Chem; 2017; 17(10):1304-1311. PubMed ID: 28270072 [TBL] [Abstract][Full Text] [Related]
14. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. Gupta AK; Paquet M J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300 [TBL] [Abstract][Full Text] [Related]
15. Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient. Mühlstädt M Dermatology; 2016; 232 Suppl 1():20-3. PubMed ID: 27513345 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. Lebwohl M; Shumack S; Stein Gold L; Melgaard A; Larsson T; Tyring SK JAMA Dermatol; 2013 Jun; 149(6):666-70. PubMed ID: 23553119 [TBL] [Abstract][Full Text] [Related]
17. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP). Tzogani K; Nagercoil N; Hemmings RJ; Samir B; Gardette J; Demolis P; Salmonson T; Pignatti F Eur J Dermatol; 2014; 24(4):457-63. PubMed ID: 25115145 [TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365 [TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Relapsing Bowen's Disease with Ingenol Mebutate: The Use of Dermoscopy to Monitor the Therapeutic Response. Mainetti C; Guillod C; Leoni-Parvex S Dermatology; 2016; 232 Suppl 1():9-13. PubMed ID: 27513936 [TBL] [Abstract][Full Text] [Related]
20. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Siller G; Gebauer K; Welburn P; Katsamas J; Ogbourne SM Australas J Dermatol; 2009 Feb; 50(1):16-22. PubMed ID: 19178487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]